Citius Oncology, Inc. (CTOR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 8, 2025, details a capital raise transaction by Citius Oncology, Inc., a Delaware corporation and emerging growth company. The report covers the entry into material definitive agreements for a registered direct offering and a concurrent private placement (collectively, the "Offering"), which closed on December 10, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $18.0 million.
- Net Proceeds: Approximately $15.2 million (after deducting placement agent fees and offering expenses).
- Securities Issued:
- 1,284,404 shares of common stock at $1.09 per share.
- 15,229,358 pre-funded warrants at a combined price of $1.0899 per unit (including accompanying common warrants).
- Common warrants to purchase up to 16,513,762 shares (1,284,404 from the direct offering and 15,229,358 from the private placement) at an exercise price of $1.09 per share.
- Placement agent warrants to purchase up to 1,155,963 shares at an exercise price of $1.3625 per share.
- Use of Proceeds: Support the commercial launch of LYMPHIR and for working capital and general corporate purposes.
- Debt Modification: The maturity of a promissory note to Citius Pharmaceuticals, Inc. was amended to extend until the Company closes capital raises aggregating at least $50 million in gross proceeds.
Material Changes and Agreements
The Company entered into securities purchase agreements with an institutional investor. A key material change involves the amendment of existing warrants (issued in July and September 2025) held by the investor. The exercise price of these existing warrants was reduced to $1.09 per share, and the exercise date was amended to commence upon Stockholder Approval. Additionally, the Company agreed to a 60-day lock-up period on issuing new equity and a one-year restriction on variable rate transactions.
Outlook, Risks, and Contingencies
- Stockholder Approval: The Company must seek stockholder approval for the issuance of shares underlying the Common Warrants within 90 days of the closing date (by March 2026) and every 90 days thereafter until approval is obtained.
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares, though this limit can be adjusted with 61 days' notice.
- Registration Rights: The Company agreed to file a registration statement for the resale of shares issuable upon exercise of the new warrants within 30 days, with effectiveness targeted within 60 to 90 days.
- Financial Contingency: The extension of the promissory note maturity is contingent on the Company raising an additional $50 million in gross proceeds through debt, equity, or royalty monetization.
Investor Verification Checklist
- Verify the status of the required stockholder approval for the Common Warrants, which must be sought within 90 days of the December 10, 2025 closing.
- Confirm the dilution impact of the 16.5 million common warrants and 1.15 million placement agent warrants on existing shareholders.
- Monitor the Company's progress toward the $50 million capital raise threshold required to extend the maturity of the Citius Pharmaceuticals promissory note.
- Review the specific terms of the amended existing warrants (July and September 2025) to understand the full scope of the investor's position.
- Assess the timeline for the commercial launch of LYMPHIR given the allocation of net proceeds.